Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Aplisol tuberculin purif prot deriv Vial 5ml 50 testby JHP Refrigerator

RX380853 380853 NDC No.42023-0104-05 42023-104-05 42023010405 4202310405 UPC/GTIN No.3-42023-10405-2 MPN 10405JHP Pharma RX380853 380853 NDC No.42023-0104-05 42023-104-05 42023010405 4202310405 UPC/GTIN No.3-42023-10405-2 MPN 10405Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Rx Item-Aplisol tuberculin purif prot deriv Vial 5ml 50 testby JHP Refrigerator

$413.29$370.99

RX380853 380853 NDC No.42023-0104-05 42023-104-05 42023010405 4202310405 UPC/GTIN No.3-42023-10405-2 MPN 10405 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX Item. Rx Item No.Rx380853 Aplisol 5 T/0.1 ml Vial 5ml by JHP Pharma Item No.3380853 NDC No.42023010405 UPC No.342023104052 Other Name Tubersol,Tuberculin Pur

Have a question?

Clinical Information
Gen. Code and Des.
9700 tuberculin,purif.prot.deriv. INTRADERM VIAL 5 T/0.1 ML
GCN and Des.
44051 tuberculin,purif.prot.deriv. INTRADERM VIAL 5 T/0.1 ML
Strength
5TU50TEST
Dose Form
VIAL (ML)
Product Category
RX Pharmaceuticals
Fine Line Class
850085008510 All Rx Products
DEA Class
NC
OMP Family

AHFS Class
36840000 TUBERCULOSIS
Active Ingredients
3087 tuberculin, purified protein derivative
Inactive Ingredients
2551 polysorbates 9005645
3199 phenol 108952




APLISOL- tuberculin purified protein derivative injection
JHP Pharmaceuticals LLC Tubersol
Diagnostic Antigen For Intradermal Injection Only
DESCRIPTION
Aplisol (tuberculin PPD, diluted) is sterile aqueous solution of purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The solution is stabilized with polysorbate (Tween) 80, buffered with potassium and sodium phosphates and contains approximately 0.35% phenol as preservative.
This product is ready for immediate use without further dilution.
The purified protein fraction is isolated from culture media filtrates of human strain of Mycobacterium tuberculosis by the method of F.B. Seibert.1,2 Tuberculin PPD, diluted, is prepared from Tuberculin PPD Powder Master Lot 154616 which is clinically bioequivalent in potency to the standard PPD-S* U** per 0.1mL) of the U.S. Public Health Service, National Centers for Disease Control. This product is made from single master lot (No. 154616) to eliminate lot to lot variation inherent in manufacturing.
The potency of each lot of tuberculin PPD, diluted is determined in sensitized guinea pigs
CLINICAL PHARMACOLOGY
Tuberculin PPD is indicated as an aid in the detection of infection with Mycobacterium tuberculosis.3,4 After person becomes infected with mycobacteria, lymphocytes proliferate and become sensitized. These sensitized cells enter the bloodstream and circulate for months or years. This sensitization process occurs principally in the regional lymph nodes and may take 2?10 weeks to develop following infection. Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancing age. The injection of tuberculin into the skin stimulates the lymphocytes and activates the series of events leading to delayed-type hypersensitivity (DTH) response. This response is called ?delayed? because the reaction becomes evident hours after injection. Dermal reactivity involves vasodilation, edema, and the infiltration of lymphocytes, basophils, monocytes, and neutrophils into the site of antigen injection. Antigen-specific lymphocytes proliferate and release lymphokines, which mediate the accumulation of other cells at the site. The area of induration reflects DTH activity.5 In most tuberculin-sensitive individuals, the delayed hypersensitivity reaction is evident 5?6 hours after administration of tuberculin skin test and is maximal 48?72 hours. In geriatric patients or in patients receiving tuberculin skin test for the first time, the reaction may develop more slowly and may not be maximal until after 72 hours.6,7 Because their immune systems are immature, many neonates and infants <6 weeks of age, who are infected with M. tuberculosis do not react at all to tuberculin tests.5
Immediate erythematous or other hypersensitivity reactions to tuberculin or the constituents of the diluent may occur at the injection site.
Tuberculin skin-test results are also less reliable as CD4 counts decline in HIV infected individuals.3
The 5TU dose of Tuberculin PPD intradermally (Mantoux) is indicated as an aid in the detection of infection with Mycobacterium tuberculosis. Reactions to the Mantoux test are interpreted on the basis of quantitative measurement of the response to specific dose U PPD-S or equivalent) of Tuberculin PPD.7
To determine that Tuberculin PPD Master Lot 154616 is clinically bioequivalent in potency to standard 5TU PPD-S*, dose-response studies were conducted in the following populations persons with history of bacteriologically confirmed TB; healthy volunteers in geographical region of low endemicity of atypical mycobacterial infection; and healthy volunteers in geographical location of high endemicity of atypical mycobacterial infection.
Aplisol Indications and USAge
Tuberculin PPD is indicated as an aid in the detection of infection with Mycobacterium tuberculosis. The standard tuberculin test employs the intradermal (Mantoux) test using 5 TU dose of tuberculin PPD.7 The 0.1 mL test dose of Aplisol (tuberculin PPD, diluted) is equivalent to the TU dose which has been clinically utilized and standardized with PPD-S. Tuberculin skin testing is not contraindicated for persons who have been vaccinated with BCG and the skin-test results of such persons are used to support or exclude the diagnosis of M. tuberculosis infections.4 HIV infection is strong risk factor for the development of TB disease in persons having TB infection. All HIV-infected persons should receive PPD-tuberculin skin test.3
info. to Patients
Patients should be instructed to report adverse events such as vesiculation, ulceration or necrosis which may occur at the test site in highly sensitive individuals. Patients should be informed that pain, pruritus and discomfort may occur at injection site.
Patients should be informed of the need to return to their physician or health care provider for the reading of the test and of the need to keep and maintain personal immunization record.
Drug Interactions
In patients who are receiving corticosteroids or immunosuppressive agents, reactivity to the test may be depressed or suppressed. This reduced reactivity may be present for as long as 5?6 weeks after discontinuation of therapy.
The reactivity to PPD may be temporarily depressed by certain live virus vaccines (measles, mumps, rubella, oral polio, yellow fever, and varicella). Therefore, if tuberculin test is to be performed, it should be administered either before the live vaccine or given simultaneously, but at separate site than the live vaccine, or testing should be postponed for 4?6 weeks.
Pregnancy
Teratogenic effects
Pregnancy Category C
DOSAGE AND ADMINISTRATION
Aplisol vials should be inspected visually for both particulate matter and discoloration prior to administration and discarded if either is seen. Vials in use for more than 30 days should be discarded.
The 0.1 mL dose of Aplisol (tuberculin PPD, diluted) is equivalent to the tuberculin units (TU) dose of Tuberculin PPD, which is the standard strength used for intradermal Mantoux testing.
Standard Method (Mantoux Test)
The Mantoux test is performed by intradermally injecting, on the volar aspect of the forearm, with syringe and needle, exactly 0.1 mL of Aplisol. The result is read 48 to 72 hours later and palpable induration only is considered in interpreting the test. Induration is hard, raised area with clearly defined margins at and around the injection site (see Interpretation of Tuberculin Reaction). ERythema may develop at the injection site but has no diagnostic value.
The standard test is performed as follows:
The site of the test is usually the volar or dorsal surface of the forearm about 4? below the elbow. Other skin sites may be used, but the volar surface of the forearm is preferred. The use of skin area free of lesions and away from any veins is recommended.7
The skin at the injection site is cleansed with 70% alcohol and allowed to dry.
The test material is administered with tuberculin syringe (0.5 or 1.0 mL) fitted with short (1/4 to 1/2?) 27 gauge needle.
A separate, sterile, single-use disposable syringe and needle should be used for each individual patient.
The diaphragm of the vial-stopper should be wiped with 70% alcohol.
The needle is inserted through the stopper diaphragm of the inverted vial. Exactly 0.1 mL is filled into the syringe with care being taken to exclude air bubbles and to maintain the lumen of the needle filled.
The point of the needle is inserted into the most superficial layers of the skin with the needle bevel pointed upward. As the Tuberculin solution is injected, pale bleb to 10 mm in size (1/3?) will rise over the point of the needle. This is quickly absorbed and no dressing is required.
There may be drop of blood when the needle is withdrawn. This is normal. Use gauze pad and gently dab to remove the blood. Do not press down as this may squeeze out the tuberculin thereby disrupting the test.
In the event the injection is delivered subcutaneously (i.e., no bleb will form), or if significant part of the dose leaks from the injection site, the test should be repeated immediately at another site at least cm (2?) removed from the initial injection site.
Interpretation of Tuberculin Reaction
Readings of Mantoux reactions should be made by trained health professional during the period from 48 to 72 hours after the injection. Induration only should be considered in interpreting the test. The diameter of induration should be measured transversely to the long axis of the forearm and recorded in millimeters. ERythema has no diagnostic value and should be disregarded. The presence and size of necrosis and edema if present should be recorded although not used in the interpretation of the test. In the absence of induration, an area of erythema greater than 10 mm in diameter may indicate the injection was made too deeply and retesting is indicated. Find the margins of the induration by drawing the index or middle finger lightly across the reaction. The tip of ballpoint pen pushed at 45? angle toward the site of injection will also stop at the edges of induration.
The diameter of induration should be measured (preferable with caliper) transversely to the long axis of the forearm and recorded in millimeters.
Positive reactions
Reaction 5 mm of induration
Reaction 10 mm of induration
Reaction 15 mm of induration
*
For persons who are otherwise at low risk and are tested at the start of employment, reaction of 15 mm induration is considered positive.
?
Risk of TB in patients treated with corticosteroids increases with higher dose and longer duration. 19
Human immunodeficiency virus (HIV)-positive persons
Recent immigrants (i.e., within the last yr) from high prevalence countries
Persons with no risk factors for TB
Recent contacts of tuberculosis (TB) case patients
Injection drug users


Fibrotic changes on chest radiograph consistent with prior TB
Residents and employees of the following high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with acquired immunodeficiency syndrome (AIDS), and homeless shelters


Patients with organ transplants and other immunosuppressed patients (receiving the equivalent of 15 mg/d of prednisone for mo or more)?
Mycobacteriology laboratory personnel




Persons with the following clinical conditions that place them at high risk: silicosis, diabetes mellitus, chronic renal failure, some hematological disorders (e.g., leukemias and lymphomas), other specific malignancies (e.g., carcinoma of the head or neck and lung), weight loss of 10% of ideal body weight, gastrectomy, and jejunoileal bypass




Children younger than yr of age or infants, children, and adolescents exposed to adults at high-risk


Skin test conversions
For persons with negative skin test reactions who undergo repeat skin testing (e.g., health care workers), an increase in reaction size 10 mm within period of years should be considered skin test conversion indicative of recent infection with M. tuberculosis. 19
In some individuals who have been infected with nontuberculous mycobacteria or have undergone BCG vaccination, the skin test may show some degree of induration. For these individuals, conversion to ?positive? is defined as an increase in induration by 10 mm on subsequent tests. 7
Healthcare facilities and other high-risk settings
For health care workers and employees in other high-risk settings with no other risk factors for TB, cut-off of 15 mm of induration (rather than 10 mm) on the tuberculin skin test should be used to define positive baseline test at the time of initial employment.
An increase of ?10 mm in reaction size is generally accepted as positive test result on subsequent testing unless the worker is contact of TB case or has HIV infection or is otherwise immunocompromised, in which case result of ?5 mm is considered positive. 21
Negative Reaction
Induration of less than 15 mm in persons with no risk factors for TB. This indicates lack of hypersensitivity to tuberculoprotein and tuberculous infection is highly unlikely.7
It should be noted that reactivity to tuberculin may be depressed or suppressed for as long as 5?6 weeks by viral infections, live virus vaccines (i.e., measles, smallpox, polio, rubella and mumps), or after discontinuation of therapy with corticosteroids or immunosuppressive agents. Malnutrition may also have similar effect (see WARNINGS). When of diagnostic importance, negative test should be accepted as proof that hypersensitivity is absent only after normal reactivity to non-specific irritants has been demonstrated. primary injection of tuberculin may possibly have boosting effect on subsequent tuberculin reactions. pediatric patient who is known to have been exposed to person with tuberculosis must not be adjudged free of infection until that patient has negative tuberculin reaction at least ten weeks after contact with tuberculous person has ceased.17 Annual testing is generally recommended for pediatric patients in high risk populations, such as persons from countries with high prevalence of tuberculosis and low-income groups.18
A positive tuberculin reaction does not necessarily signify the presence of active disease. Further diagnostic procedures (e.g., chest radiograph, sputum smear and/or culture examination) should be carried out before diagnosis of tuberculosis is made. small percentage of responders may not have been infected with M. tuberculosis but by some other mycobacterium. The negative tuberculin skin test should never be used to exclude the possibility of active tuberculosis among persons for whom the diagnosis is being considered (symptoms compatible with tuberculosis).
Booster Effect and Two-Step Testing
Infection of an individual with tubercle bacilli or other mycobacteria or BCG vaccination results in delayed hypersensitivity response to tuberculin which is demonstrated by the skin test. The delayed hypersensitivity response may gradually wane over period of years. If person receives tuberculin test at this time, significant reaction may not be detected. However, the stimulus of the test may boost or increase the size of the reaction to second test, sometimes causing an apparent conversion or development of sensitivity. This booster effect can be seen on second test done one week after the initial stimulating test and can persist for year, and perhaps longer. When routine periodic tuberculin testing of adults is done, initially two-stage testing should be considered to minimize the likelihood of interpreting boosted reaction as conversion.7,15,16
In this testing method, persons who have negative initial skin test undergo second tuberculin skin test 1-3 weeks after the first. Both tests should be read and recorded at 48 to 72 hours. Those individuals with positive reaction on the second test should be considered to be previously infected, and those with negative reaction on the second test should be considered uninfected. In these uninfected persons, positive result on any future skin test should be interpreted as skin test conversion. 7
HOW SUPPLIED
Tuberculin PPD-Aplisol bioequivalent to US units (TU) PPD-S per test dose (0.1 mL) is available in the following presentations:



RX380853 380853 NDC No.42023-0104-05 42023-104-05 42023010405 4202310405 UPC/GTIN No.3-42023-10405-2 MPN 10405
Aplisol 5 T 0.1 ml Vial 5ml by JHP Pharm
RX380853 380853 NDC No.42023-0104-05 42023-104-05 42023010405 4202310405 UPC/GTIN No.3-42023-10405-2 MPN 10405

JHP Pharma RX380853 380853 NDC No.42023-0104-05 42023-104-05 42023010405 4202310405 UPC/GTIN No.3-42023-10405-2 MPN 10405
AmericanPharmaWholesale.com
JHP Pharma RX380853 380853 NDC No.42023-0104-05 42023-104-05 42023010405 4202310405 UPC/GTIN No.3-42023-10405-2 MPN 10405

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
TUBERCULIN,PURIF.PROT.DER
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.